Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.
Impressive preclinical studies have prompted Boehringer Ingelheim GMBHto license OSE Immunotherapeutics SA' s novel checkpoint inhibitor antibody that's designed to treat advanced solid tumors, in a deal that could generate up €1.1bn for the French biotech.
The pact, announced April 4, gives the Germany-based group global rights to develop, register and commercialize OSE-172, which has obtained...
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
